Proactive High-Dose IV Iron Is Preferred Therapy in ESKD Patients: PRO
- 24 February 2022
- journal article
- editorial
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (2) , 208-210
Abstract
This is an Early Access article. Please select the PDF button, above, to view it. Be sure to also read the CON: 10.34067/KID.0007152020 and the COMMENTARY 10.34067/KID.0004892021Keywords
This publication has 12 references indexed in Scilit:
- Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populationsHeliyon, 2019
- Intravenous Iron in Patients Undergoing Maintenance HemodialysisNew England Journal of Medicine, 2019
- Iron Overload in Dialysis Patients: Rust or Bust?Kidney International Reports, 2017
- Effects of Ferric Carboxymaltose on Hospitalisations and Mortality Rates in Iron-Deficient Heart Failure Patients: An Individual Patient data Meta-AnalysisEuropean Journal of Heart Failure, 2017
- The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit TrialKidney International, 2012
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2009
- Serum Ferritin Level Remains a Reliable Marker of Bone Marrow Iron Stores Evaluated by Histomorphometry in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2009
- Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin SaturationJournal of the American Society of Nephrology, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinNew England Journal of Medicine, 1998